UA99633C2 - Антитело, специфически связывающееся с человеческим белком ron - Google Patents

Антитело, специфически связывающееся с человеческим белком ron

Info

Publication number
UA99633C2
UA99633C2 UAA201006208A UAA201006208A UA99633C2 UA 99633 C2 UA99633 C2 UA 99633C2 UA A201006208 A UAA201006208 A UA A201006208A UA A201006208 A UAA201006208 A UA A201006208A UA 99633 C2 UA99633 C2 UA 99633C2
Authority
UA
Ukraine
Prior art keywords
ron
macrophage
inhibition
treatment
methods
Prior art date
Application number
UAA201006208A
Other languages
English (en)
Ukrainian (uk)
Inventor
Деніел Перейра
Дженніфер О'Тул
Original Assignee
Імклоун Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99633(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Імклоун Ллк filed Critical Імклоун Ллк
Publication of UA99633C2 publication Critical patent/UA99633C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к антителу или его фрагменту, специфически связывающемуся с человеческим белком RON, для лечения заболеваний, таких как рак. Также данное изобретение относится к фармацевтической композиции, содержащей данное антитело, и способу угнетения ангиогенеза, роста опухолей, пролиферации опухолевых клеток с помощью указанного антитела.
UAA201006208A 2007-11-21 2008-11-21 Антитело, специфически связывающееся с человеческим белком ron UA99633C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98955807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
UA99633C2 true UA99633C2 (ru) 2012-09-10

Family

ID=40364492

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201006208A UA99633C2 (ru) 2007-11-21 2008-11-21 Антитело, специфически связывающееся с человеческим белком ron

Country Status (20)

Country Link
US (2) US7947811B2 (ru)
EP (1) EP2222703A2 (ru)
JP (1) JP5324593B2 (ru)
KR (1) KR101227338B1 (ru)
CN (1) CN101868478B (ru)
AR (1) AR069393A1 (ru)
AU (1) AU2008330089B2 (ru)
BR (1) BRPI0820218A2 (ru)
CA (1) CA2706583A1 (ru)
CL (1) CL2008003449A1 (ru)
EA (1) EA018717B1 (ru)
IL (1) IL204743A (ru)
MX (1) MX2010005651A (ru)
NZ (1) NZ584271A (ru)
PA (1) PA8804901A1 (ru)
PE (1) PE20091713A1 (ru)
TW (1) TWI417106B (ru)
UA (1) UA99633C2 (ru)
UY (1) UY31478A1 (ru)
WO (1) WO2009070294A2 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP2245066A2 (en) * 2008-01-22 2010-11-03 Biogen Idec MA Inc. Ron antibodies and uses thereof
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
PL2519543T3 (pl) * 2009-12-29 2016-12-30 Białka wiążące heterodimery i ich zastosowania
JP2013533746A (ja) 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｒｏｎ抗体
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2699256B1 (en) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions and methods for the treatment of neuromyelitis optica
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
JP2015505818A (ja) 2011-11-14 2015-02-26 ファイブ プライム セラピューティックス インコーポレイテッド 癌を治療する方法
RU2015125642A (ru) * 2012-11-30 2017-01-11 Дженентек, Инк. Композиции ron и способы их применения
RU2015140921A (ru) * 2013-02-26 2017-04-03 Роше Гликарт Аг Антитела к mcsp
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
CN107517590B (zh) * 2014-07-29 2021-11-12 威马克生物有限公司 与表皮生长因子受体-靶制剂有关的感受性预测用新型生物标志物及其用途
US11946934B2 (en) * 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
CN109923129A (zh) * 2016-08-26 2019-06-21 新加坡科技研究局 巨噬细胞刺激蛋白受体（或RON-Recepteur d,Origine Nantais）抗体及其用途
WO2018052789A1 (en) 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
CA3192706A1 (en) * 2020-09-15 2022-03-24 Gregory SEMPOWSKI Coronavirus antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE221915T1 (de) 1991-02-22 2002-08-15 American Cyanamid Co Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP1299419A2 (en) * 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
AU2001295002B2 (en) 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
SE518548C2 (sv) 2001-04-11 2002-10-22 Sca Hygiene Prod Ab Absorberande alster med förbättrad diskretion
US7235523B2 (en) * 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
SI1487856T1 (sl) 2002-03-04 2010-12-31 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr (receptor z domeno kinaznega vkljuäśka) in njihove uporabe
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) * 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
US20090246205A1 (en) * 2004-05-13 2009-10-01 Imclone Systems, Inc Inhibition of macrophage-stimulating protein receptor (ron)

Also Published As

Publication number Publication date
AU2008330089A1 (en) 2009-06-04
TWI417106B (zh) 2013-12-01
PE20091713A1 (es) 2009-11-13
US20110135631A1 (en) 2011-06-09
MX2010005651A (es) 2010-06-11
WO2009070294A2 (en) 2009-06-04
KR20100074293A (ko) 2010-07-01
WO2009070294A3 (en) 2009-08-20
AR069393A1 (es) 2010-01-20
CN101868478B (zh) 2013-11-13
CL2008003449A1 (es) 2010-02-19
UY31478A1 (es) 2009-07-17
PA8804901A1 (es) 2009-06-23
BRPI0820218A2 (pt) 2015-06-23
IL204743A (en) 2013-10-31
TW200936161A (en) 2009-09-01
JP5324593B2 (ja) 2013-10-23
IL204743A0 (en) 2010-11-30
CA2706583A1 (en) 2009-06-04
JP2011504176A (ja) 2011-02-03
US7947811B2 (en) 2011-05-24
AU2008330089B2 (en) 2013-09-05
NZ584271A (en) 2012-05-25
KR101227338B1 (ko) 2013-01-28
US20090136510A1 (en) 2009-05-28
CN101868478A (zh) 2010-10-20
EA018717B1 (ru) 2013-10-30
EP2222703A2 (en) 2010-09-01
US8133489B2 (en) 2012-03-13
EA201070636A1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
UA99633C2 (ru) Антитело, специфически связывающееся с человеческим белком ron
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
NZ754051A (en) Novel antibodies and uses thereof
UA102867C2 (ru) Антитела к cxcr4 и их применение в лечении рака
TN2012000555A1 (en) Antibodies to human gdf8
JO2576B1 (en) Antibodies
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
WO2007127010A3 (en) Diarylthiohydantoin compounds
WO2007149427A3 (en) Tyrosine kinase inhibitors
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
WO2007146957A3 (en) Ror1 as a therapeutic target for lung cancer
NO20090608L (no) Tyrosinkinaseinhibitorer
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
WO2009051957A3 (en) Antibodies to irem-1
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
UA99716C2 (ru) Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
WO2010129048A3 (en) Therapeutic compounds
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use